Correction: Enhanced Recovery in Gynecologic Oncology Surgery —State of the Science
(Source: Current Oncology Reports)
Source: Current Oncology Reports - September 28, 2023 Category: Cancer & Oncology Source Type: research

Exercise as Medicine in Cardio-Oncology: Reducing Health Disparities in Hispanic and Latina Breast Cancer Survivors
AbstractPurpose of ReviewThis review aims to access the current state of the evidence in exercise as medicine for cardio-oncology in Hispanic and Latina breast cancer survivors and to provide our preliminary data on the effects of supervised aerobic and resistance training on cardiovascular disease (CVD) risk in this population.Recent FindingsBreast cancer survivors have a higher risk of CVD; particularly Hispanic and Latina breast cancer survivors have a higher burden than their White counterparts. Exercise has been shown to reduce CVD risk in breast cancer survivors; however, evidence in Hispanic and Latina breast cancer...
Source: Current Oncology Reports - September 16, 2023 Category: Cancer & Oncology Source Type: research

Chemotherapy-Induced Peripheral Neuropathy: Diagnosis, Agents, General Clinical Presentation, and Treatments
AbstractPurpose of ReviewThis review aims to discuss pathophysiology, diagnosis, clinical presentation, and treatment of chemotherapy-induced peripheral neuropathy. Agent-specific presentation and pathophysiology is also being discussed.Recent FindingsAs new systemic oncological treatments continue to be developed, the number of cancer survivors continues to grow. Survivors are living longer with the long-term side effects of oncological treatments. We reviewed the pathophysiology of agent-specific chemotherapy-induced peripheral neuropathy and the updates in its treatment and preventative tools.SummaryChemotherapy-induced...
Source: Current Oncology Reports - September 13, 2023 Category: Cancer & Oncology Source Type: research

New Developments in Image-Guided Percutaneous Irreversible Electroporation of Solid Tumors
AbstractPurpose of ReviewThis review will describe the various applications, benefits, risks, and approaches of conventional irreversible electroporation (IRE), as well as highlight the new technological developments of this procedure along with their clinical applications.Recent FindingsMinimally invasive image-guided percutaneous IRE ablation has emerged as a newer, non-thermal ablation technique for tumors in the solid organs, particularly within the liver, pancreas, kidney, and prostate. IRE allows for ablation near heat-sensitive structures, including major blood vessels and nerves, and is not susceptible to the heat ...
Source: Current Oncology Reports - September 11, 2023 Category: Cancer & Oncology Source Type: research

Correction to: Extramammary Paget Disease: a Therapeutic Challenge, for a Rare Entity
(Source: Current Oncology Reports)
Source: Current Oncology Reports - September 11, 2023 Category: Cancer & Oncology Source Type: research

Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
AbstractPurpose of ReviewThis review provides an update on the developments of adjuvant and neoadjuvant liver-directed and systemic therapy options for patients with resectable hepatocellular carcinoma.Recent FindingsData on liver-directed treatment in the adjuvant and neoadjuvant settings are sparse and results are conflicting; many studies suggest that optimizing patient selection criteria is a key milestone required to improve study design and clinical benefit to patients. Systemic treatment options are primarily focused on investigation of anti-PD-1/L1 immunotherapeutic agents, either alone or in combination with other...
Source: Current Oncology Reports - September 9, 2023 Category: Cancer & Oncology Source Type: research

Approach to the Older Patient with Acute Myeloid Leukemia
This study aims to review the challenges of treating AML in older patients, the spectrum of genomic aberrancies in this cohort, and discuss treatment options for newly diagnosed AML in this patient population.Recent FindingsGreater understanding of biological underpinnings of AML and availability of newer, effective, targeted therapies have allowed us to move away from intensification of chemotherapy, to prioritize better tolerability while still maintaining efficacy.SummaryIncreasing knowledge of the genomic complexity and adverse karyotypes in older AML patients drives the need for ongoing investigations of targeted and ...
Source: Current Oncology Reports - September 9, 2023 Category: Cancer & Oncology Source Type: research

Next-Generation Sequencing —Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
AbstractPurpose of ReviewThis research paper aims to provide an overview of evidence-based sequencing of therapies in relapsed/refractory chronic lymphocytic leukemia (CLL) in the era of targeted drugs.Recent FindingsIn the absence of data from randomized clinical trials comparing novel agents head-to-head, growing evidence suggests that patients with late relapse (> 2 years) after fixed-duration therapies benefit from identical retreatment, whereas a class switch is favorable in those with short-lived remissions or progressive disease on continuous drug intake. Treatment of patients previously exposed to both covalent ...
Source: Current Oncology Reports - September 8, 2023 Category: Cancer & Oncology Source Type: research

Interventional Treatment Options for Post-mastectomy Pain
AbstractPurpose of ReviewBreast cancer is currently the most prevalent cancer diagnosed globally, and there is a significant gap in the availability of effective first-line treatment options. In addition to a cancer diagnosis, breast cancer patients face additional pain and morbidity after treatment. Radiation fibrosis, muscle spasms, muscle pain, neuropathy, and limited shoulder function are all potential side effects of breast cancer treatment and breast reconstruction. Post-mastectomy pain syndrome affects 25 –60% of people after breast surgery. The current review moves forward to explain interventional pain managemen...
Source: Current Oncology Reports - August 30, 2023 Category: Cancer & Oncology Source Type: research

Cellular Therapy in NSCLC: Between Myth and Reality
AbstractPurpose of ReviewIn this paper, we review the current state and modalities of adoptive cell therapies (ACT) in non-small cell lung carcinoma (NSCLC). We also discuss the challenges hampering the use of ACT and the approaches to overcome these barriers.Recent FindingsSeveral trials are ongoing investigating the three main modalities of T cell-based ACT: tumor-infiltrating lymphocytes (TILs), genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T cells. The latter, in particular, has revolutionized the treatment of hematologic malignancies. However, the efficacy against solid tumor is s...
Source: Current Oncology Reports - August 30, 2023 Category: Cancer & Oncology Source Type: research

Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors
This study aimed to evaluate the possible interaction between RT and CDK inhibitors in the adjuvant setting for patients with positive hormone receptors and HER-2 negative, investigating toxicity and the treatment sequencing.Recent findingsCDK inhibitors have been studied in patients with localized breast cancer and can improve invasive disease-free survival outcomes. Regarding the time of RT, all trials used  CDK inhibitors after the RT. Interruptions in the CDK inhibitors were performed in 27.1% in Pallas, 17.5% in Penelope-B, and 16.6% in Monarch-E trials due to adverse events. Data from the Natalee trial are still no...
Source: Current Oncology Reports - August 25, 2023 Category: Cancer & Oncology Source Type: research

Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients
AbstractPurpose of ReviewThis review paper is intended to show that changes in body composition are key in the pathogenesis of bone fragility amongst patients with breast and prostate cancer receiving hormone deprivation therapies (HDTs) and that the mechanism is based on the development of alterations in bone quality rather than in bone quantity.Recent FindingsPreclinical and clinical data suggest a tight connection amongst bone, adipose and muscular tissues by means of several soluble mediators, potentially leading to (1) bone resorption and bone quality deterioration in sarcopenic obese subjects, (2) bone mineral deposi...
Source: Current Oncology Reports - August 25, 2023 Category: Cancer & Oncology Source Type: research

Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment
AbstractPurpose of ReviewExtrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare, aggressive malignancy that can arise from any organ and frequently presents with distant metastases. Advanced disease has a poor prognosis with median overall survival (OS) rarely exceeding 1 year even with systemic therapy. The management paradigm of advanced/metastatic EP-NEC has been extrapolated from small cell lung cancer (SCLC) and commonly consists of 1st line therapy with etoposide and platinum (cisplatin or carboplatin), followed by alternative cytotoxic regimens at the time of progression. Only a minority of patients are able to ...
Source: Current Oncology Reports - August 22, 2023 Category: Cancer & Oncology Source Type: research

Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets
AbstractPurpose of ReviewThe pathogenesis of dedifferentiated chondrosarcoma is controversial, and no genetic abnormality has consistently been identified in the disease. Focusing on the diagnostic challenges encountered in dedifferentiated chondrosarcoma, the following review aims at summarizing the tumor ’s active neoplastic pathways while highlighting therapeutic modalities that could potentially be explored to enhance patient survivorship.Recent FindingsOwing to the challenging examination of small needle biopsy sampling as well as the disease ’s overlapping morphological and immunohistochemical features with other...
Source: Current Oncology Reports - August 21, 2023 Category: Cancer & Oncology Source Type: research

Cardiac Arrhythmias in Oncological Patients —Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
AbstractPurpose of ReviewTo provide an update on epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients within the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology.Recent FindingsOne of the side effects of different chemotherapeutics is their pro-arrhythmic activity. Both atrial and ventricular arrhythmias may be induced by cancer itself or by anticancer treatment. Recent studies report on the cardiotoxic activity of such promising therapies as BRAF and MEK inhibitors, or CAR-T therapy.SummaryRisk factors of arrhythmias in oncological patients overlap w...
Source: Current Oncology Reports - August 17, 2023 Category: Cancer & Oncology Source Type: research